When children survive cancer, what does the future hold for their health? This is a vital question for the 250,000 cancer survivors under age 30 in the United States.

For decades, physicians and scientists at Cincinnati Children’s have been working to advance knowledge about survivorship and speed the transfer of that knowledge from the laboratory to patient care.

Stella Davies, MBBS, PhD, MRCP, director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s, is leading national studies to improve the lives of childhood cancer survivors.

Using DNA collected from more than 14,000 childhood cancer survivors across the country, the Davies lab is researching genetic markers to predict susceptibility to treatment side effects, secondary cancers and other long-term health complications. Her research will help improve personalized cancer treatments based on a patient’s genetic profile, as well as follow-up care for aging survivors.

Specific research under way in our Cancer and Blood Diseases Institute focuses on:

  • The identification of patients who are at high risk for late complications or secondary cancers
  • The causes of early heart and lung disease in cancer survivors
  • New approaches to improve fertility outcomes
  • The evaluation and treatment of neurological and psychological side effects
  • New ways to prevent secondary cancers and other complications associated with cancer treatment